German Adrenocortical Carcinoma Registry

Learn more about:
Related Clinical Trial
Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

German Adrenocortical Carcinoma Registry

Official Title

Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry

Brief Summary

      Basic objective of the German Adrenocortical Carcinoma Registry is to improve the care of
      patients with adrenocortical cancer. The registration of as many patients as possible helps
      to collect data for the prognosis and prospects of success regarding different treatment
      plans. This data will be taken into consideration for planning prospective studies. With this
      registry, the recruitment of patients for prospective studies will be significantly
      facilitated. In this way - and in cooperation with networks in other countries (e.g. in Italy
      and France) - a structure allowing systematic improvement of therapy will be developed.
    



Study Type

Observational




Condition

Adrenocortical Carcinoma


Study Arms / Comparison Groups

 Adrenocortical carcinoma
Description:  Adrenocortical carcinoma

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

1000

Start Date

January 2003

Completion Date

December 2025

Primary Completion Date

December 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of adrenocortical carcinoma
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Martin Fassnacht, MD, 49-931-201-36507, [email protected]

Location Countries

Germany

Location Countries

Germany

Administrative Informations


NCT ID

NCT00453674

Organization ID

Wue-ACC-R-86-03


Responsible Party

Principal Investigator

Study Sponsor

University of Wuerzburg

Collaborators

 Deutsche Krebshilfe e.V., Bonn (Germany)

Study Sponsor

Martin Fassnacht, MD, Principal Investigator, University of Wuerzburg


Verification Date

August 2018